CoChat

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review

Open access
Deng, You, Park, Andrew, Zhu, Lin, Xie, Wen, Pan, Calvin Q. · 2022 · Therapeutic Advances in Chronic Disease

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Background & Objective: Although data on the effects of liraglutide and semaglutide in patients with diabetes have been reviewed, their therapeutic outcomes in obese/overweight individuals without diabetes have not been summarized. We conducted a systematic review to evaluate their effects on the latter population. Methods: We searched the PubMed, EMBASE, Cochrane, CNKI, and Wanfang databases. Studies regarding obese/overweight adults without diabetes treated with liraglutide/semaglutide compared with other active agents or placebos were accessed. The primary outcomes were the proportions of adults with at least 5% and 10% weight reduction. The secondary outcomes included metabolic indicators and adverse events. Results: Eighteen studies with 10,938 obese/overweight adults without diabetes were included. When stratified by the categories of at least 5% and 10% weight loss, the pooled data showed medians 27.7% and 10.3% of control groups versus 65.3% and 30.7% of liraglutide 3 mg once daily, respectively; whereas medians 47.6% and 20.4% of control groups vs 86.6% and 75.3% of semaglutide 2.4 mg once weekly were found in the two categories, respectively. Both agents either improved or had no impact on lipid or glycemia. Liraglutide or semaglutide therapy had discontinuation rates of 2.4%–11.4% which overlapped with 0.7%–8.6% in control groups. The frequency of adverse events was comparable between the treatment groups and the control groups (66.5%–95.8% vs 46.9%–96.1%), which were mild to moderate graded by studies. Conclusion: Liraglutide and semaglutide therapy led to a clinically relevant (⩾5%) weight loss of 48.2%–88.7% among obese/overweight adults without diabetes. Both liraglutide and semaglutide are associated with weight loss and are well-tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/20406223221108064

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Data search and collection process. The flowchart presented the process of identifying articles in the systematic review. Among 4,902 articles found, 621 were removed as duplicates, and 4,106 did not meet the inclusion criteria. After screening the rest of the 175 articles, 157 were removed due to the exclusion criteria. The remaining 18 articles were included in the systematic review (12 RCTs and 6 non-RCTs).
Figure 1. Data search and collection process. The flowchart presented the process of identifying articles in the systematic review. Among 4,902 articles found, 621 were removed as duplicates, and 4,106 did not meet the inclusion criteria. After screening the rest of the 175 articles, 157 were removed due to the exclusion criteria. The remaining 18 articles were included in the systematic review (12 RCTs and 6 non-RCTs).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 2

  1. Zhou JL, 2018, J Pract Diabetol, 2018, 13
  2. Sauer N, 2015, Horm Metab Res, 47, 560

Cited by

See all 57

Metadata

Authors
Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q.
Affiliations
  • Capital Medical University (CN)
  • Northern Valley Regional High School at Old Tappan, Old Tappan, NJ, USA
Corresponding author
Xie, Wen
Venue
Therapeutic Advances in Chronic Disease
Published
2022-01
Volume
13
Pages
20406223221108064-20406223221108064
ISSN
  • 2040-6223 (ISSN-L)
  • 2040-6231
OpenAlex
W4285035640
Cited by
51
References
54
Citations by year
2026: 7 · 2025: 17 · 2024: 14 · 2023: 13
FWCI
1.58
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Chronic Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation Youth Fund Project (81600454)
  • Clinical Medicine Development Project of Beijing Municipal Administration of Hospitals (ZYLX201828)
  • National Natural Science Foundation of China (81770577)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
semaglutide, liraglutide, obesity, overweight, weight loss, GLP-1 receptor agonists, non-diabetic adults, adverse events, treatment discontinuation, glycemic control, lipid profile

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. https://app.cochat.ai/papers/10.1177/20406223221108064
The paper
Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022). Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/20406223221108064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.